Morgan Stanley’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,088
| Closed | -$2.61K | – | 8155 |
|
|
2024
Q2 | $2.61K | Hold |
1,088
| – | – | ﹤0.01% | 7020 |
|
|
2024
Q1 | $5.35K | Sell |
1,088
-2,000
| -65% | -$10K | ﹤0.01% | 6877 |
|
|
2023
Q4 | $12.9K | Sell |
3,088
-532
| -15% | -$4.01K | ﹤0.01% | 6569 |
|
|
2023
Q3 | $54.4K | Hold |
3,620
| – | – | ﹤0.01% | 6134 |
|
|
2023
Q2 | $106K | Sell |
3,620
-150
| -4% | -$4.64K | ﹤0.01% | 5931 |
|
|
2023
Q1 | $86.9K | Hold |
3,770
| – | – | ﹤0.01% | 6071 |
|
|
2022
Q4 | $54.3K | Sell |
3,770
-5
| -0.1% | -$96 | ﹤0.01% | 6253 |
|
|
2022
Q3 | $91K | Sell |
3,775
-2,599
| -41% | -$67K | ﹤0.01% | 6133 |
|
|
2022
Q2 | $127K | Sell |
6,374
-6,050
| -49% | -$134K | ﹤0.01% | 6148 |
|
|
2022
Q1 | $447K | Buy |
12,424
+6,154
| +98% | +$229K | ﹤0.01% | 5476 |
|
|
2021
Q4 | $281K | Buy |
6,270
+282
| +5% | +$16.9K | ﹤0.01% | 5881 |
|
|
2021
Q3 | $426K | Buy |
5,988
+202
| +3% | +$23K | ﹤0.01% | 5591 |
|
|
2021
Q2 | $764K | Buy |
5,786
+4,684
| +425% | +$586K | ﹤0.01% | 5243 |
|
|
2021
Q1 | $148K | Sell |
1,102
-930
| -46% | -$118K | ﹤0.01% | 5820 |
|
|
2020
Q4 | $148K | Buy |
2,032
+1,985
| +4,223% | +$146K | ﹤0.01% | 5740 |
|
|
2020
Q3 | $3K | Sell |
47
-188
| -80% | -$12.6K | ﹤0.01% | 6539 |
|
|
2020
Q2 | $18K | Sell |
235
-87
| -27% | -$5.91K | ﹤0.01% | 6038 |
|
|
2020
Q1 | $13K | Sell |
322
-143
| -31% | -$10.9K | ﹤0.01% | 5962 |
|
|
2019
Q4 | $37K | Buy |
+465
| New | +$33.2K | ﹤0.01% | 5939 |
|
Other funds holding ASLN
Morgan Stanley's ASLN Position: Q3 2024 in Review
Morgan Stanley sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2024, closing a stake of 1,088 shares — an estimated $2.61K sold.
Morgan Stanley first reported a position in ASLN in Q4 2019 and held it in 19 quarters. The position peaked at $764K in Q2 2021. 1 fund tracked by Wall St. Rank holds ASLN as of Q3 2024.
- Morgan Stanley reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2024 after selling out during the quarter.
- Morgan Stanley sold 1,088 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2024, an estimated $2.61K.
- Morgan Stanley first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2019 and held it in 19 quarters.
- Morgan Stanley's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $764K in Q2 2021.
- 1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2024.
Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.